Clinical trials
Renal Carcinoma clinical trials
Below are recruiting renal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 287 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06553339RecruitingPhase 1
A study of HS-10516 for VHL syndrome tumors
This trial tests a new drug called HS-10516 in people with VHL syndrome or advanced kidney cancer. The goal is to see if the drug can shrink tumors and what side effects it might have.
Beijing, Beijing MunicipalityAges 18–80 - NCT06601296RecruitingPhase 2
Radiation plus immunotherapy for metastatic kidney cancer
This trial tests whether combining radiation therapy with two types of immunotherapy (checkpoint inhibitors and an injectable drug called IMSA101) can help control metastatic kidney cancer that is only growing in a few spots. The goal is to see if this approach can shrink tumors and keep them from growing further.
Dallas, TexasAges 18 years+ - NCT06613269RecruitingPhase 2
PET-guided radiation therapy for clear cell kidney cancer
This trial tests whether a special PET/CT scan (68Ga-NY104) can help guide radiation therapy for people with clear cell kidney cancer. The goal is to make radiation more precise and effective for treating tumors that haven't spread too much.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06652022Recruiting
Radiation plus drugs vs drugs alone for limited spread bladder cancer
This trial tests whether adding targeted radiation to standard drug therapy can help people with a limited number of bladder or urinary tract cancer metastases. It's for those whose cancer has spread to a few spots that can be treated with full coverage radiation.
BeijingAges 18–80 - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06690697RecruitingPhase 2
Toripalimab and JS004 for advanced kidney cancer
This trial tests a combination of two drugs, toripalimab and JS004, for patients with advanced kidney cancer that has returned or spread. It aims to see if this therapy can help when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06730672RecruitingPhase 2
Testing voronib plus everolimus for advanced kidney cancer
This trial tests a combination of two drugs — voronib and everolimus — for people with clear cell kidney cancer whose previous targeted therapy and immunotherapy have stopped working. The goal is to see if this new combination can help when other treatments have failed.
Guangzhou, GuangdongAges 18 years+ - NCT06750419RecruitingPhase 3
Imaging test for clear cell kidney cancer before surgery
This study tests a special imaging agent (89Zr-TLX250) to help doctors see clear cell kidney cancer during PET/CT scans. It is for people in China who have a single small kidney mass and are already scheduled for surgery to remove it.
BeijingAges 18 years+ - NCT06783348RecruitingPhase 2
Radioactive treatment for advanced kidney cancer
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
CaenAges 18–100 - NCT06839105RecruitingPhase 1
Testing AWT020 for advanced cancers
This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.
Fuzhou, FujianAges 18 years+ - NCT06883539RecruitingPhase 1
Study of LXP1788 for advanced solid tumors
This trial tests a new drug called LXP1788 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how it affects the body.
TaichungAges 18 years+ - NCT07024680Recruiting
Sunitinib or sorafenib for papillary kidney cancer
This study looks at how well sunitinib or sorafenib work as a first treatment for a type of kidney cancer called papillary renal cell carcinoma (PRCC) that cannot be removed with surgery or has spread. It aims to understand real-world results in Chinese patients.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07038733Recruiting
Lymph node study for kidney cancer patients
This study looks at lymph nodes in people with known or suspected kidney cancer to learn more about the disease. It may help researchers understand how kidney cancer affects the lymph system.
New Haven, ConnecticutAges 18 years+ - NCT07077161RecruitingPhase 2
Skipping Cabozantinib Doses Instead of Reducing Them
This trial tests whether skipping a dose of cabozantinib instead of lowering the dose can help manage side effects while still controlling your kidney cancer. It is for people already taking cabozantinib who might need a break but want to stay on treatment.
Leiden, South HollandAges 18 years+ - NCT07160335RecruitingPhase 1
Testing a potential biosimilar for multiple resected solid tumors
This trial tests whether a new drug, HLX17, works as well as the approved drug Keytruda® in people whose solid tumors (like lung cancer, melanoma, or kidney cancer) have been fully removed by surgery. The goal is to see if the new drug can help prevent the cancer from coming back.
Glendale, CaliforniaAges 18–85 - NCT07167329RecruitingPhase 2
Belzutifan for VHL syndrome: a real-world study
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
São Paulo, São PauloAges 14 years+ - NCT07172386RecruitingPhase 2
Pre-surgery treatment for advanced kidney cancer
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07172802RecruitingPhase 1/Phase 2
Study of GI-108 for advanced solid tumors
This trial tests a new drug called GI-108, which is designed to help your immune system fight cancer. It is for people with advanced or metastatic solid tumors that have not responded to other treatments.
SeoulAges 18 years+ - NCT07234409Recruiting
Robotic partial nephrectomy for small kidney tumors
This trial compares different surgical methods for removing kidney tumors using a single-port robot. It aims to find the best approach for treating stage 1 kidney cancer.
MilanAges 18 years+ - NCT07234656Recruiting
Study on fear of cancer returning in kidney cancer
This study looks at fear of cancer recurrence in people with kidney cancer and their partners. It aims to understand and help manage these fears. You and your partner may join if you had surgery for early-stage kidney cancer.
AalborgAges Any age - NCT07292168RecruitingPhase 1/Phase 2
Study of a new antibody for advanced tumors with FGFR1 protein
This trial tests an experimental antibody, OM-RCA-01, in people with advanced solid tumors that have high levels of a protein called FGFR1. It aims to see if the drug is safe and effective for those who have already tried other treatments.
Kazan'Ages 18 years+ - NCT07386158RecruitingPhase 2
Immunotherapy before surgery for clear cell kidney cancer
This trial tests whether giving pucotenlimab (an immunotherapy drug) with vorolanib (a targeted therapy) before surgery helps shrink clear cell kidney tumors and makes kidney-sparing surgery safer. It is for people with localized, non-metastatic disease where the tumor is difficult to remove with partial nephrectomy.
Guangzhou, Other (Non U.s.)Ages 18–85 - NCT07389629RecruitingPhase 2
Combination therapy before surgery for kidney cancer
This trial tests a new drug combination given before surgery for kidney cancer that is early stage but hard to operate on. The goal is to shrink the tumor and make surgery easier.
GuangzhouAges 18–80 - NCT00102544Enrolling by invitation
Tracking Devices to Find Abnormalities During Medical Procedures
This study tests technology that uses imaging scans to help doctors locate and reach abnormalities during surgical or interventional procedures. The goal is to make these image-guided procedures more accurate and safer for patients.
Bethesda, MarylandAges 18–120
Hear when a new Renal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for renal carcinoma?
- Yes. Clin2 currently lists 287 recruiting renal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a renal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a renal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.